Hikal Ltd
NSE:HIKAL

Watchlist Manager
Hikal Ltd Logo
Hikal Ltd
NSE:HIKAL
Watchlist
Price: 399.45 INR -1.38% Market Closed
Market Cap: 49.3B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one HIKAL stock under the Base Case scenario is 515.42 INR. Compared to the current market price of 399.45 INR, Hikal Ltd is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIKAL Relative Value
Base Case
515.42 INR
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.7
P/S
P/S
Price to Sales
2.7
vs History
15
vs Industry
41
Median 3Y
2.1
Median 5Y
2
Industry
2.4
Forward
2.5
More Details
66
P/E
P/E
Price to Earnings
66
vs History
6
vs Industry
6
Median 3Y
49.7
Median 5Y
40.4
Industry
20.8
Forward
66.9
More Details
19.5
P/OCF
P/OCF
Price to OCF
19.5
vs History
26
vs Industry
22
Median 3Y
17.1
Median 5Y
14.1
Industry
15.4
More Details
106.8
P/FCFE
P/FCFE
Price to FCFE
106.8
vs History
42
vs Industry
4
Median 3Y
105.6
Median 5Y
102.6
Industry
22.8
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
23
vs Industry
17
Median 3Y
3.5
Median 5Y
3.4
Industry
2
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
15
vs Industry
38
Median 3Y
2.3
Median 5Y
2.2
Industry
2.5
Forward
2.7
More Details
5.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.4
vs History
25
vs Industry
36
Median 3Y
4.8
Median 5Y
4.6
Industry
4.9
More Details
18
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
18
vs History
12
vs Industry
20
Median 3Y
15.7
Median 5Y
15.1
Industry
12.7
Forward
17.6
More Details
31.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
31.2
vs History
7
vs Industry
14
Median 3Y
27.2
Median 5Y
24.2
Industry
15.8
Forward
30.6
More Details
21.1
EV/OCF
EV/OCF
Enterprise Value to OCF
21.1
vs History
25
vs Industry
21
Median 3Y
18
Median 5Y
15
Industry
14
More Details
50.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
50.5
vs History
46
vs Industry
9
Median 3Y
50.9
Median 5Y
48.3
Industry
18.3
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
23
vs Industry
29
Median 3Y
2.1
Median 5Y
2.1
Industry
1.7
More Details

Multiples Across Competitors

HIKAL Competitors Multiples
Hikal Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Hikal Ltd
NSE:HIKAL
49.3B INR 2.7 66 18 31.2
US
Eli Lilly and Co
NYSE:LLY
782.6B USD 17.4 73.9 42.9 47.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
399.2B USD 4.5 28.4 13.3 17.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.2 20.7 13.6 15.5
CH
Roche Holding AG
SIX:ROG
231.6B CHF 3.9 20.1 11.2 13.3
CH
Novartis AG
SIX:NOVN
198.1B CHF 4.4 18.8 11.4 14.6
UK
AstraZeneca PLC
LSE:AZN
174.5B GBP 4.2 32.1 126.8 193.6
US
Merck & Co Inc
NYSE:MRK
227.3B USD 3.5 13.3 9 10.6
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 17.9 8.5 12.1
P/E Multiple
Earnings Growth PEG
IN
Hikal Ltd
NSE:HIKAL
Average P/E: 32.4
66
37%
1.8
US
Eli Lilly and Co
NYSE:LLY
73.9
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28.4
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
20.7
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.1
16%
1.3
CH
Novartis AG
SIX:NOVN
18.8
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.1
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13.3
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.9
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Hikal Ltd
NSE:HIKAL
Average EV/EBITDA: 397.1
18
20%
0.9
US
Eli Lilly and Co
NYSE:LLY
42.9
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.3
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.2
8%
1.4
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.8
9%
14.1
US
Merck & Co Inc
NYSE:MRK
9
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Hikal Ltd
NSE:HIKAL
Average EV/EBIT: 1 702.6
31.2
28%
1.1
US
Eli Lilly and Co
NYSE:LLY
47.4
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.4
12%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
15.5
16%
1
CH
Roche Holding AG
SIX:ROG
13.3
9%
1.5
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
193.6
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.6
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
HIKAL intrinsic value, competitors valuation, and company profile.
DCF Valuation
HIKAL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HIKAL stock valuation using valuation multiples.
Wall Street Estimates
HIKAL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HIKAL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.